早期産NEOnatesおよび早期血管老化危険因子(NEOVASC)における独占的な母乳 (NEOVASC)
早期血管老化の危険因子(NEOVASC)に対する早産新生児における完全な母乳ダイエットの影響
Early vascular aging has its origins in fetal and neonatal life. The NEOVASC clinical trial aims to determine the effects of an exclusive human milk diet in extremely preterm infants on long-term cardiovascular health.
調査の概要
詳細な説明
Early vascular aging has its origins in fetal and neonatal life. This early period of life plays an important role in the development of obesity, high blood pressure, abnormalities in lipid metabolism and non-insulin dependent diabetes. Increased cardiovascular risk in formerly preterm infants constitutes a health problem of steadily growing relevance. Emerging evidence suggests that human milk feeding has substantial benefits to the health of all infants, especially for those born prematurely. Unfortunately, human milk alone does not provide sufficient concentrations of nutrients, especially calcium, phosphorus, protein, and fat needed for these infants to grow satisfactorily. For that purpose, fortifiers are used to help increase the nutritional value of human milk.
The NEOVASC study is a multicentric, prospective, randomized, controlled, open and parallel group clinical trial. A total of 200 extremely preterm infants and 100 term infants are recruited for the test and control group, respectively. Infants in the test group (i.e., premature neonates) are randomized to either:
- An exclusive human milk diet which contains mother's milk or pasteurized donor human milk and a human milk fortifier until 36 weeks of gestation; OR
- Human milk (as long as available) and a human milk fortifier (as long as human milk is available) until a maximum of 32 weeks of gestation and thereafter human milk with a bovine-based fortifier or preterm formula.
After 36 weeks of gestation, human milk with a bovine-based fortifier or preterm formula is used in both groups. As a control group, term-born age-matched controls are included. Participants within this control group are not enrolled at the time of birth but instead recruited in various kindergartens at the age of five. Therefore, data from birth is taken from the mother-child-booklet, which contains clinical records about the pregnancy, birth and early life of children born in Austria. The total study duration is scheduled for 96 months with a recruitment phase of 36 months. Follow-up visits are planned at one, two and five years of age for the test group.
The purpose of the NEOVASC clinical trial is to characterize early life stressors by assessing the effects of a physiological (i.e., human milk-based) nutrition in extremely preterm infants during the vulnerable preterm period on the risk of metabolic and vascular complications in later life. Outcomes include predictors and intermediate components of cardiovascular disease.
研究の種類
入学 (推定)
段階
- 適用できない
連絡先と場所
研究連絡先
- 名前:Ursula Kiechl-Kohlendorfer, MD, MSc
- 電話番号:+43 512 504 27309
- メール:ursula.kohlendorfer@i-med.ac.at
研究連絡先のバックアップ
- 名前:Wolfgang Mitterer, MD
- 電話番号:+43 670 2021490
- メール:wolfgang.mitterer@student.i-med.ac.at
研究場所
-
-
Tyrol
-
Innsbruck、Tyrol、オーストリア、A-6020
- 募集
- Medical University of Innsbruck
-
コンタクト:
- Ursula Kiechl-Kohlendorfer, MD, MSc
- 電話番号:+43 512 504 27309
- メール:ursula.kohlendorfer@i-med.ac.at
-
コンタクト:
- Wolfgang Mitterer, MD
- メール:wolfgang.mitterer@student.i-med.ac.at
-
主任研究者:
- Christoph Binder, MD
-
主任研究者:
- Martin Wald, MD
-
主任研究者:
- Burkhard Simma, MD
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Preterm-born group:
Inclusion Criteria:
- Extremely preterm infants with a birth weight of 500-1250g.
- Feeding is NPO or exclusive human milk prior to enrollment.
- Parent(s) willing to sign informed consent.-
Exclusion Criteria:
- Infants with a birth weight <500g or >1250g
- Subjects diagnosed with inborn errors of metabolism such as galactosemia, phenylketonuria
- Subjects who have not been NPO or fed exclusive human milk diet prior to enrollment.
- Presence of major congenital malformation.
- Presence of intestinal perforation or Stage 2 Necrotizing enterocolitis prior to enrollment.
- Parent(s) not willing to sign informed consent.
- Unable to participate for any reason based on the decision of the study investigator (e.g. unlikely to survive the study period).
Term-born group:
Inclusion criteria
- Term-born children with an adequate birth weight
- Parent(s) willing to sign informed consent
Exclusion criteria
- Subjects with acute or chronic illness
- Parent(s) not willing to sign informed consent
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:独身
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
アクティブコンパレータ:Randomized study product group
receiving study product (human milk fortifier "Humavant") until a gestational age of 36 weeks |
Premature infants are randomized to either:
After 36 weeks of gestation, human milk with a bovine-based fortifier or preterm formula is used in both groups. As a control group, term-born age-matched controls are included. |
|
アクティブコンパレータ:Randomized control group
receiving study product until a gestational age of 32 weeks and reference product (bovine based fortifier or bovine formula) after 32 weeks of gestation |
Premature infants are randomized to either:
After 36 weeks of gestation, human milk with a bovine-based fortifier or preterm formula is used in both groups. As a control group, term-born age-matched controls are included. |
|
介入なし:Term control group
Term-born controls as a reference group for outcome parameters |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Fasting blood glucose
時間枠:"First day of life" up to "five years of life"
|
Primary outcome is the difference in fasting blood glucose at five years of age |
"First day of life" up to "five years of life"
|
|
Blood pressure
時間枠:"First day of life" up to "five years"
|
Primary outcome is the difference in blood pressure at five years of age |
"First day of life" up to "five years"
|
|
Distensibility of aorta
時間枠:"First day of life" up to "five years"
|
Primary outcome is the difference in the distensibility of the descending aorta using validated echocardiographic protocols at five years of age |
"First day of life" up to "five years"
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Fasting blood glucose
時間枠:"First day of life" up to "24 months"
|
Secondary outcome is fasting glucose at a corrected age of one and two years. |
"First day of life" up to "24 months"
|
|
Blood pressure
時間枠:"First day of life" up to "24 months"
|
Secondary outcome is blood pressure at a corrected age of one and two years. |
"First day of life" up to "24 months"
|
|
BMI
時間枠:"First day of life" up to "five years"
|
Secondary outcome is BMI at five years of age, weight in kilograms and height in meters will be combined to report BMI in kg/m2 |
"First day of life" up to "five years"
|
|
Insulin sensitivity
時間枠:"First day of life" up to "five years"
|
Secondary outcome is insulin sensitivity at five years of age |
"First day of life" up to "five years"
|
|
Lipid profile
時間枠:"First day of life" up to "five years"
|
Secondary outcome is lipid profile at five years of age |
"First day of life" up to "five years"
|
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Fasting blood glucose
時間枠:"five years of age"
|
Difference in fasting blood glucose between preterm- and term-born children at five years of age |
"five years of age"
|
|
Blood pressure
時間枠:"five years of age"
|
Difference in blood pressure between preterm- and term-born children at five years of age |
"five years of age"
|
|
Distensibility of the descending aorta
時間枠:"five years of age"
|
Difference in the distensibility of the descending aorta between preterm- and term-born children using validated echocardiographic protocols at five years of age Results will be compared to results of term-born children |
"five years of age"
|
|
BMI
時間枠:"five years of age"
|
Difference in BMI between preterm- and term-born children at five years of age, weight in kilograms and height in meters will be combined to report BMI in kg/m2 |
"five years of age"
|
|
Insulin sensitivity
時間枠:"five years of age"
|
Difference in insulin sensitivity between preterm- and term-born children at five years of age |
"five years of age"
|
|
Lipid profile
時間枠:"five years of age"
|
Difference in lipid profile between preterm- and term-born children at five years of age |
"five years of age"
|
協力者と研究者
スポンサー
協力者
捜査官
- 主任研究者:Ursula Kiechl-Kohlendorfer, MD, MSc、Medical University Innsbruck
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。